Cue Biopharma Announces $50.0 Million Private Placement
Rhea-AI Summary
Cue Biopharma (Nasdaq:CUE) entered a securities purchase agreement for a $50.0 million private placement with accredited investors, comprising 1,418,071 common shares at $33.21 per share and pre-funded warrants for up to 87,500 shares at $33.209 each. The pre-funded warrants are immediately exercisable at $0.001 per share and remain exercisable until fully exercised. Closing is expected on or about July 13, 2026, subject to customary conditions. The placement is led by Cormorant Asset Management with additional new funds including Columbia Threadneedle Investments. Cue Biopharma plans to use net proceeds to support clinical development and general corporate purposes and highlights upcoming data from Ascendant Health’s ongoing Phase 2 CSU study in China, expected by the end of the third quarter of 2026. The securities are unregistered under the Securities Act, and the company has agreed to file a registration statement for resale.
Positive
- Gross proceeds of approximately $50.0 million from private placement
- 1,418,071 common shares sold at $33.21 per share plus 87,500 pre-funded warrants
- Financing led by Cormorant Asset Management with participation from new institutional investors
- Net proceeds earmarked to fund clinical development and general corporate purposes
- Upcoming Phase 2 CSU study data in China expected by end of Q3 2026
Negative
- Issuance of 1,418,071 shares and up to 87,500 warrant shares implies equity dilution for existing holders
- Securities are unregistered under the Securities Act, limiting offers and sales absent registration or exemption
News Market Reaction – CUE
In the Jul 10 session, CUE gained 0.74%, reflecting a mild positive market reaction. Argus tracked a peak move of +23.3% during that session. Argus tracked a trough of -15.2% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Private placement Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Private placement financing | Positive | +106.4% | Announced $30M private placement to fund Ascendant-221 and general purposes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past private placement news for Cue Biopharma coincided with a very large positive share-price reaction.
Key Terms
pre-funded warrants financial
securities purchase agreement financial
registration rights agreement regulatory
accredited investors financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of
The private placement is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of
The private placement was led by Cormorant Asset Management, with participation from additional new investment funds including Columbia Threadneedle Investments.
The Company intends to use the net proceeds from the private placement to further fund clinical development and for other general corporate purposes.
“We are pleased to have such a high-quality group of biotech investors committing to the long-term support of Cue as we build our company and advance our portfolio targeting functional cures across immunological disorders,” said Shao-Lee Lin, M.D., Ph.D., chief executive officer, president and board director of Cue Biopharma. “We look forward to our upcoming clinical milestones, including data from Ascendant Health’s ongoing Phase 2 CSU study in China, which is expected by the end of the third quarter of 2026.”
The securities being issued and sold in the private placement, including the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock sold in the private placement and the shares of common stock underlying the pre-funded warrants sold in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the expected closing of, and anticipated use of proceeds from, the private placement and the company’s anticipated clinical milestones. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, market conditions and the satisfaction of customary closing conditions related to the private placement, and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor and Media Contact
Agnes Lee
Chief Officer of Public and Investor Relations
Marie Campinell
Senior Director, Corporate Communications
ir@cuebio.com
Cue Biopharma, Inc.
